133 related articles for article (PubMed ID: 32019732)
1. Adequate Engraftment With Lower Hematopoietic Stem Cell Dose.
Jeyaraman P; Borah P; Dayal N; Pathak S; Naithani R
Clin Lymphoma Myeloma Leuk; 2020 Apr; 20(4):260-263. PubMed ID: 32019732
[TBL] [Abstract][Full Text] [Related]
2. Factors that predict delayed platelet recovery after autologous stem cell transplantation for lymphoma or myeloma.
Nagayama T; Ashizawa M; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Mashima K; Umino K; Minakata D; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Yamamoto C; Fujiwara SI; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Ann Hematol; 2020 Dec; 99(12):2893-2901. PubMed ID: 32572522
[TBL] [Abstract][Full Text] [Related]
3. Lenograstim versus filgrastim in mobilization before autologous hematopoietic stem cell transplantation in patients with multiple myeloma and lymphoma - Single center experience.
Sarıcı A; Erkurt MA; Bahçecioğlu ÖF; Biçim S; Berber İ; Gök S; Kaya E; Özgül M; Kuku İ
Transfus Apher Sci; 2021 Aug; 60(4):103127. PubMed ID: 33863669
[TBL] [Abstract][Full Text] [Related]
4. Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
Liang EC; Muffly LS; Shiraz P; Shizuru JA; Johnston L; Arai S; Frank MJ; Weng WK; Lowsky R; Rezvani A; Meyer EH; Negrin R; Miklos DB; Sidana S
Transplant Cell Ther; 2021 May; 27(5):405.e1-405.e6. PubMed ID: 33775587
[TBL] [Abstract][Full Text] [Related]
5. Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma.
Jang G; Ko OB; Kim S; Lee DH; Huh J; Suh C
Transfusion; 2008 Apr; 48(4):640-6. PubMed ID: 18194384
[TBL] [Abstract][Full Text] [Related]
6. Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma.
Stiff PJ; Micallef I; Nademanee AP; Stadtmauer EA; Maziarz RT; Bolwell BJ; Bridger G; Marulkar S; Hsu FJ; DiPersio JF
Biol Blood Marrow Transplant; 2011 Aug; 17(8):1146-53. PubMed ID: 21126595
[TBL] [Abstract][Full Text] [Related]
7. Safety and survival outcomes for bloodless transplantation in patients with myeloma.
Joseph NS; Kaufman JL; Boise LH; Valla K; Almaula DK; Obidike CO; Langston AA; Waller EK; Khoury HJ; Flowers CR; Graiser M; Heffner LT; Lonial S; Nooka AK
Cancer; 2019 Jan; 125(2):185-193. PubMed ID: 30480777
[TBL] [Abstract][Full Text] [Related]
8. Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation.
Elayan MM; Horowitz JG; Magraner JM; Shaughnessy PJ; Bachier C
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1921-5. PubMed ID: 26033279
[TBL] [Abstract][Full Text] [Related]
9. Influence of laboratory procedures on postthawing cell viability and hematopoietic engraftment after autologous peripheral blood stem cell transplantation.
Belisário AR; da Costa Funes AP; Luz JR; de Almeida Costa L; Furtado MDSBS; Martins MC; Cruz NG; Pederzoli PRMP; de Andrade RK; Libânio MRIS; de Lima Prata K
Transfusion; 2021 Apr; 61(4):1202-1214. PubMed ID: 33569783
[TBL] [Abstract][Full Text] [Related]
10. Ideal body weight correlates better with engraftment after PBSC autograft than actual body weight, but is under-estimated in myeloma patients possibly due to disease-related height loss.
Maclean PS; Parker AN; McQuaker IG; Clark AD; Farrell E; Douglas KW
Bone Marrow Transplant; 2007 Oct; 40(7):665-9. PubMed ID: 17646841
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human thrombopoietin improved platelet engraftment after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
Gu J; Liu J; Li X; Zou W; Huang B; Chen M; Li J
Cancer Med; 2021 Nov; 10(21):7641-7649. PubMed ID: 34569193
[TBL] [Abstract][Full Text] [Related]
12. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
[TBL] [Abstract][Full Text] [Related]
13. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
14. CXCR4 expression on transplanted peripheral blood CD34+ cells: relationship to engraftment after autologous transplantation in a cohort of multiple myeloma patients.
Hicks C; Isaacs A; Wong R; Chong BH
Ann Hematol; 2011 May; 90(5):547-55. PubMed ID: 20957366
[TBL] [Abstract][Full Text] [Related]
15. Role of the CD34+ 38- cells in posttransplant hematopoietic recovery.
Hénon P; Sovalat H; Bourderont D; Ojeda-Uribe M; Arkam Y; Wunder E; Raidot JP; Husseini F; Audhuy B
Stem Cells; 1998; 16 Suppl 1():113-22. PubMed ID: 11012153
[TBL] [Abstract][Full Text] [Related]
16. Granulocyte colony-stimulating factor utilization postautologous hematopoietic stem cell transplant in multiple myeloma patients: Does one size fit all?
Jackson ER; Jared JR; Piccolo JK; Woo KM; Mably MS; Reed MP; Callander NS
J Oncol Pharm Pract; 2019 Jul; 25(5):1135-1141. PubMed ID: 29890920
[TBL] [Abstract][Full Text] [Related]
17. Are myeloma patients with renal failure candidates for autologous stem cell transplantation?
San Miguel JF; Lahuerta JJ; García-Sanz R; Alegre A; Bladé J; Martinez R; García-Laraña J; De La Rubia J; Sureda A; Vidal MJ; Escudero A; Pérez-Esquiza E; Conde E; García-Ruiz JC; Cabrera R; Caballero D; Moraleda JM; Leon A; Besalduch J; Hernandez MT; Rifon J; Hernandez F; Solano C; Palomera L; Parody R; Gonzalez JD; Mataix R; Maldonado J; Constela J; Carrera D; Bello JL; De Pablos JM; Pérez-Simón JA; Torres JP; Olanguren J; Prieto E; Acebede G; Peñarrubia MJ; Torres P; Díez-Martín JL; Rivas A; Sánchez JM; Díaz-Mediavilla J
Hematol J; 2000; 1(1):28-36. PubMed ID: 11920166
[TBL] [Abstract][Full Text] [Related]
18. Pegfilgrastim improves the outcomes of mobilization and engraftment in autologous hematopoietic stem cell transplantation for the treatment of multiple myeloma.
Ding X; Huang W; Peng Y; Fan H; Zhu Y; Liu X; Yang Y; Guo Q; Qiu L; Dai Y; Zou D; Jin F
Ann Hematol; 2020 Jun; 99(6):1331-1339. PubMed ID: 32382775
[TBL] [Abstract][Full Text] [Related]
19. The effect of comorbidity on survival and collected CD34 + cell counts in autologous hematopoietic stem cell transplant patients.
Sarıcı A; Erkurt MA; Kuku İ; Bahçecioğlu ÖF; Biçim S; Kaya E; Berber İ; Keser MF; Gök S; Özgül M
Transfus Apher Sci; 2022 Feb; 61(1):103296. PubMed ID: 34696982
[TBL] [Abstract][Full Text] [Related]
20. [The efficacy and safety of bortezomib-based induction regimen before autologous hematopoietic stem cell transplantation in patients with multiple myeloma].
Li J; Liu JR; Huang BH; Chen M; Zheng D; Xu DR; Zou WY
Zhonghua Nei Ke Za Zhi; 2012 Apr; 51(4):279-83. PubMed ID: 22781947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
